Novartis Oncology and NIBR collaborate to form TCO; our group accelerates innovative oncology compounds from target discovery to commercialization. TCO aims to advance patient outcomes in early trials by selecting patients based on the molecular mechanism of drugs and diseases.
The TCO function is responsible for: developing the strategy and executing first-in-human and proof-of-concept clinical trials for oncology therapeutics using adaptive design; developing and executing biomarker and imaging strategies in clinical trials; providing robust research support to Oncology compounds to increase clinical trial success and maximize patient benefit through patient stratification, indication expansion, and combination therapy; managing of global clinical trials using patient selection and targeted therapies; and ensuring a smooth hand-off to full development to advance medicines to market.
Our fellow will learn to: ° Lead and participate in the clinical trial team to impact study design, conduct, and analysis ° Develop clinical trial protocols ° Contribute to the design of data capture tools and statistical analysis plans ° Create and obtain essential regulatory trial documents ° Orchestrate selection and oversight of clinical trial sites and external vendors ° Participate in the analysis of study data and the preparation of final study reports ° Contribute to of Investigator’s Brochure, briefing books, and safety updates
To be considered for an interview at Midyear, please register for both ASHP Midyear and PPS and then complete a fellowship application on the MCPHS Fluid Review application portal. Visit https://mcphs.fluidreview.com/
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via PPS to schedule interviews.
Before ASHP Midyear Clinical Meeting
Applicants must upload the following application materials to the online portal prior to December 2, 2019:
Letter of intent
Unofficial college transcript
Contact information of three references for recommendations
Incomplete applications WILL NOT be reviewed. ASHP Clinical Midyear Meeting interviews CANNOT be scheduled until these materials have been submitted. Please keep in mind that this is a competitive process and applicants are encouraged to complete their applications as soon as possible.
After ASHP Midyear Clinical Meeting
The three recommendations must be submitted by the three provided contacts no later than December 16th.
Top candidates will be invited for onsite interviews at the Novartis Institutes for BioMedical Research location in Cambridge, Massachusetts. Final candidates will be required to go through additional screening /onboarding as required by MCPHS University.
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis, with interviews at the American Society of Health Systems Pharmacists (ASHP) Midyear meeting.
Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the one or two-year fellowship. No visa sponsorship will be provided.
About MCPHS University/Novartis Institutes for BioMedical Research
The Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis. We are committed to discovering innovative medicines to treat diseases with high unmet medical need. With more than 6,000 scientists and physicians around the world, our open and entrepreneurial culture encourages collaboration as we work to push the boundaries of science to change the practice of medicine.